Neurovascular regulation in the normal brain and in Alzheimer's disease

Key Points

  • The rate of cerebral blood flow (CBF) is positively correlated with brain activity. This 'functional hyperaemia' is mediated by the coordinated action of various vasoactive agents — including ions that are associated with synaptic transmission and some neurotransmitters — on blood vessels.

  • The increases in CBF that are associated with neural activity are spatially restricted to the site of activity. Local interneurons and astrocytes are probably crucial to regulation of CBF at this level, producing and releasing vasoactive mediators.

  • Vasodilation of extracerebral arteries that supply the site of neural activity is probably achieved through the upstream transmission of vasoactive signals within the walls of blood vessels.

  • The 'neurovascular unit' — a functional entity comprising neurons, astrocytes, smooth muscle cells and endothelial cells — has a key role in the haemodynamic response to brain activity.

  • Disruption of this regulatory network occurs in response to brain injury; for example, during stroke. Evidence now indicates that cerebrovascular dysfunction is a feature of neurodegenerative disorders such as Alzheimer's disease.

  • Accumulation of amyloid β-peptide (Aβ) in brain is associated with neuronal death in Alzheimer's disease. Aβ induces dysfunction in all cell types of the neurovascular unit and interferes with the function of blood vessels. These effects are mediated through reactive oxygen species.

Abstract

The structural and functional integrity of the brain depends on the delicate balance between substrate delivery through blood flow and energy demands imposed by neural activity. Complex cerebrovascular control mechanisms ensure that active brain regions receive an adequate amount of blood, but the nature of these mechanisms remains elusive. Recent findings implicate perivascular neurons, gliovascular interactions and intramural vascular signalling in the control of the cerebral microcirculation. Neurons, astrocytes and vascular cells seem to constitute a functional unit, the primary purpose of which is to maintain the homeostasis of the brain's microenvironment. Alterations of these vascular regulatory mechanisms lead to brain dysfunction and disease. The emerging view is that cerebrovascular dysregulation is a feature not only of cerebrovascular pathologies, such as stroke, but also of neurodegenerative conditions, such as Alzheimer's disease.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: The ionic currents that are produced by axon potentials and synaptic processing generate extracellular field potentials.
Figure 2: Evoked neural events that underlie the increase in cerebral blood flow (CBF).
Figure 3: Vasoactive mediators released from neurons and glia by neural activity.
Figure 4: Local and propagated microvascular responses following activation of the somatosensory cortex.
Figure 5: Putative cellular mechanisms for the propagation of vasodilation from vessels in the activated site (arterioles and capillaries) to resistance arteries upstream (pial arteries).
Figure 6: Representative sources and targets of vascular reactive oxygen species (ROS).
Figure 7: Hypothetical time-course of the interplay between vascular dysregulation, neuropathological alterations (plaques, neurofibrillary tangles, synaptic loss) and decline in brain function in Alzheimer's disease.
Figure 8: Potential interactions between vascular factors (oligaemia) and amyloid β-peptide (Aβ) in the regulation of brain dysfunction in early (left) and late (right) Alzheimer's disease.

References

  1. 1

    Hossmann, K. -A. Viability thresholds and the penumbra of focal ischemia. Ann. Neurol. 36, 557–565 (1994). This paper provides an appraisal of the effects of reduction in CBF on brain metabolism and function.

  2. 2

    Van Lieshout, J. J., Wieling, W., Karemaker, J. M. & Secher, N. H. Syncope, cerebral perfusion, and oxygenation. J. Appl. Physiol. 94, 833–848 (2003).

  3. 3

    Imai, Y., Ohkubo, T., Tsuji, I., Satoh, H. & Hisamichi, S. Clinical significance of nocturnal blood pressure monitoring. Clin. Exp. Hypertens. 21, 717–727 (1999).

  4. 4

    Sander, D., Winbeck, K., Klingelhofer, J. & Conrad, B. Extent of cerebral white matter lesions is related to changes of circadian blood pressure rhythmicity. Arch. Neurol. 57, 1302–1307 (2000).

  5. 5

    Heistad, D. & Kontos, H. in Handbook of Physiology: The Cardiovascular System III (eds Abboud, F. & Shephard, J.) 137–182 (American Physiological Society, Bethesda, 1983). An in-depth discussion of cerebrovascular autoregulation and a comprehensive review of the cerebrovascular literature up to the early 1980s.

  6. 6

    Logothetis, N. K. The underpinnings of the BOLD functional magnetic resonance imaging signal. J. Neurosci. 23, 3963–3971 (2003). An accurate and approachable presentation of the neurophysiological bases of the BOLD signal.

  7. 7

    Mathiesen, C., Caesar, K., Akgoren, N. & Lauritzen, M. Modification of activity-dependent increases of cerebral blood flow by excitatory synaptic activity and spikes in rat cerebellar cortex. J. Physiol. (Lond.) 512, 555–566 (1998).

  8. 8

    Logothetis, N. K., Pauls, J., Augath, M., Trinath, T. & Oeltermann, A. Neurophysiological investigation of the basis of the fMRI signal. Nature 412, 150–157 (2001). References 7 and 8 provide evidence that spiking activity and CBF are not necessarily linked.

  9. 9

    Caesar, K., Thomsen, K. & Lauritzen, M. Dissociation of spikes, synaptic activity, and activity-dependent increments in rat cerebellar blood flow by tonic synaptic inhibition. Proc. Natl Acad. Sci. USA 100, 16000–16005 (2003).

  10. 10

    Mosso, A. Sulla circolazione del cervello dell'uomo. Atti R. Accad. Lincei 5, 237–358 (1880).

  11. 11

    Iadecola, C. Regulation of the cerebral microcirculation during neural activity: is nitric oxide the missing link? Trends Neurosci. 16, 206–214 (1993).

  12. 12

    Roy, C. & Sherrington, C. On the regulation of the blood-supply of the brain. J. Physiol. (Lond.) 11, 85–108 (1890).

  13. 13

    Heuser, D. in Cerebral Vascular Smooth Muscle and its Control (eds Elliot, K. & O'Connor, M.) 339–353 (Elsevier, New York, 1978).

  14. 14

    Uddman, R. & Edvinsson, L. Neuropeptides in the cerebral circulation. Cerebrovasc. Brain Metab. Rev. 1, 230–252 (1989).

  15. 15

    Edvinsson, L. & Krause, D. N. in Cerebral Blood Flow and Metabolism (eds Edvinsson, L. & Krause, D. N.) 191–211 (Lippincott, Williams and Wilkins, Philadelphia, 2002). A comprehensive source addressing the main aspects of the structure and function of the cerebral circulation.

  16. 16

    Fergus, A. & Lee, K. S. GABAergic regulation of cerebral microvascular tone in the rat. J. Cereb. Blood Flow Metab. 17, 992–1003 (1997).

  17. 17

    Hamel, E. Cholinergic modulation of the cortical microvascular bed. Prog. Brain. Res. 145, 171–178 (2004).

  18. 18

    Faraci, F. M. & Breese, K. R. Nitric oxide mediates vasodilation in response to activation of N-methyl-D-aspartate receptors in brain. Circ. Res. 72, 476–480 (1993). This paper first implicated NO in the mechanisms of the increase in CBF produced by activation of NMDA receptors.

  19. 19

    Bhardwaj, A. et al. P-450 epoxygenase and NO synthase inhibitors reduce cerebral blood flow response to N-methyl-D-aspartate. Am. J. Physiol. Heart Circ. Physiol. 279, H1616–1624 (2000).

  20. 20

    Buerk, D. G., Ances, B. M., Greenberg, J. H. & Detre, J. A. Temporal dynamics of brain tissue nitric oxide during functional forepaw stimulation in rats. Neuroimage 18, 1–9 (2003).

  21. 21

    Niwa, K., Araki, E., Morham, S. G., Ross, M. E. & Iadecola, C. Cyclooxygenase-2 contributes to functional hyperemia in whisker-barrel cortex. J. Neurosci. 20, 763–770 (2000).

  22. 22

    Iliff, J. J., D'Ambrosio, R., Ngai, A. C. & Winn, H. R. Adenosine receptors mediate glutamate-evoked arteriolar dilation in the rat cerebral cortex. Am. J. Physiol. Heart Circ. Physiol. 284, H1631–1637 (2003).

  23. 23

    Lassen, N. A. Brain extracellular pH: the main factor controlling cerebral blood flow. Scand. J. Clin. Lab. Invest. 22, 247–251 (1968).

  24. 24

    Plum, F. in Cerebral Vascular Smooth Muscle and its Control (eds Elliot, K. & O'Connor, M.) 3–7 (Elsevier, New York, 1978).

  25. 25

    Ko, K. R., Ngai, A. C. & Winn, R. H. Role of adenosine in regulation of regional cerebral blood flow in sensory cortex. Am. J. Physiol. 259, H1703–H1708 (1990).

  26. 26

    Peng, X. et al. Suppression of cortical functional hyperemia to vibrissal stimulation in the rat by epoxygenase inhibitors. Am. J. Physiol. Heart Circ. Physiol. 283, H2029–2037 (2002).

  27. 27

    Dirnagl, U., Lindauer, U. & Villringer, A. Role of nitric oxide in the coupling of cerebral blood flow to neural activation in rats. Neurosci. Lett. 149, 43–46 (1993).

  28. 28

    Yang, G., Chen, G., Ebner, T. J. & Iadecola, C. Nitric oxide is the predominant mediator of cerebellar hyperemia during somatosensory activation in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 277 R1760–R1770 (1999).

  29. 29

    Hayashi, T. et al. Neuronal nitric oxide has a role as a perfusion regulator and a synaptic modulator in cerebellum but not in neocortex during somatosensory stimulation — an animal PET study. Neurosci. Res. 44, 155–165 (2002).

  30. 30

    Ma, J., Ayata, C., Huang, P. L., Fishman, M. C. & Moskowitz, M. A. Regional cerebral blood flow response to vibrissal stimulation in mice lacking type I NOS gene expression. Am. J. Physiol. Heart. Circ. Physiol. 270 H1085–1090 (1996).

  31. 31

    Yang, G., Zhang, Y., Ross, M. E. & Iadecola, C. Attenuation of activity-induced increases in cerebellar blood flow in mice lacking neuronal nitric oxide synthase. Am. J. Physiol. Heart. Circ. Physiol. 285, H298–304 (2003).

  32. 32

    Cholet, N., Seylaz, J., Lacombe, P. & Bonvento, G. Local uncoupling of the cerebrovascular and metabolic responses to somatosensory stimulation after neuronal nitric oxide synthase inhibition. J. Cereb. Blood Flow Metab. 17, 1191–1201 (1997).

  33. 33

    Gotoh, J. et al. Regional differences in mechanisms of cerebral circulatory response to neuronal activation. Am. J. Physiol. Heart. Circ. Physiol. 280, H821–829 (2001).

  34. 34

    Ances, B. M., Buerk, D. G., Greenberg, J. H. & Detre, J. A. Temporal dynamics of the partial pressure of brain tissue oxygen during functional forepaw stimulation in rats. Neurosci. Lett. 306, 106–110 (2001).

  35. 35

    Cooper, R. S., Papakostopoulos, D. & Crow, H. J. in Blood Flow and Metabolism in the Brain (eds Harper, A. M., Jennett, B., Miller, D. L. & Rowan, J.) 14.8–14.9 (Churchill Livingstone, New York, 1975).

  36. 36

    Vanzetta, I. & Grinvald, A. Increased cortical oxidative metabolism due to sensory stimulation: implications for functional brain imaging. Science 286, 1555–1558 (1999).

  37. 37

    Ances, B. M. Coupling of changes in cerebral blood flow with neural activity: what must initially dip must come back up. J. Cereb. Blood Flow Metab. 24, 1–6 (2004).

  38. 38

    Mintun, M. A. et al. Blood flow and oxygen delivery to human brain during functional activity: theoretical modeling and experimental data. Proc. Natl Acad. Sci. USA 98, 6859–6864 (2001).

  39. 39

    Powers, W. J., Hirsch, I. B. & Cryer, P. E. Effect of stepped hypoglycemia on regional cerebral blood flow response to physiological brain activation. Am. J. Physiol. 270, H554–559 (1996).

  40. 40

    Attwell, D. & Iadecola, C. The neural basis of functional brain imaging signals. Trends Neurosci 25, 621–615 (2002). This review proposes that the increase in CBF evoked by activation is linked to synaptic signalling rather than to the metabolic needs of the tissue.

  41. 41

    Mintun, M. A., Vlassenko, A. G., Rundle, M. M. & Raichle, M. E. Increased lactate/pyruvate ratio augments blood flow in physiologically activated human brain. Proc. Natl Acad. Sci. USA 101, 659–664 (2004).

  42. 42

    Ido, Y., Chang, K. & Williamson, J. R. NADH augments blood flow in physiologically activated retina and visual cortex. Proc. Natl Acad. Sci. USA 101, 653–648 (2004).

  43. 43

    Ido, Y., Chang, K., Woolsey, T. A. & Williamson, J. R. NADH: sensor of blood flow need in brain, muscle, and other tissues. Faseb J. 15, 1419–1421 (2001).

  44. 44

    Silva, A. C. & Koretsky, A. P. Laminar specificity of functional MRI onset times during somatosensory stimulation in rat. Proc. Natl Acad. Sci. USA 99, 15182–15187 (2002).

  45. 45

    Norup Nielsen, A. & Lauritzen, M. Coupling and uncoupling of activity-dependent increases of neuronal activity and blood flow in rat somatosensory cortex. J. Physiol. (Lond.) 533, 773–785 (2001).

  46. 46

    Chaigneau, E., Oheim, M., Audinat, E. & Charpak, S. Two-photon imaging of capillary blood flow in olfactory bulb glomeruli. Proc. Natl Acad. Sci. USA 100, 13081–13086 (2003). This paper provides striking evidence of the spatial accuracy of the changes in CBF produced by neural activity.

  47. 47

    Freund, T. F. Interneuron diversity series: rhythm and mood in perisomatic inhibition. Trends Neurosci. 26, 489–495 (2003).

  48. 48

    Cauli, B., Tong, X. K., Lambolez, B., Rossier, J. & Hamel, E. Stimulation of distinct populations of GABA interneurons elicits changes in local microvessel diameter in the rat cerebral cortex. Soc. Neurosci. Abstr. 889.13 (2003).

  49. 49

    Iadecola, C., Arneric, S., Baker, H., Tucker, L. & Reis, D. Role of local neurons in the cerebrocortical vasodilation elicited from cerebellum. Am. J. Physiol. Regul. Integr. Comp. Physiol. 252, R1082–1091 (1987).

  50. 50

    Iadecola, C., Li, J., Yang, G. & Xu, S. Neural mechanisms of blood flow regulation during synaptic activity in cerebellar cortex. J. Neurophysiol. 75, 940–950 (1996).

  51. 51

    Yang, G., Huard, J. M., Beitz, A. J., Ross, M. E. & Iadecola, C. Stellate neurons mediate functional hyperemia in the cerebellar molecular layer. J. Neurosci. 20, 6968–6973 (2000). This paper provides direct evidence that cerebellar interneurons control local blood flow.

  52. 52

    Wu, D. M., Kawamura, H., Sakagami, K., Kobayashi, M. & Puro, D. G. Cholinergic regulation of pericyte-containing retinal microvessels. Am. J. Physiol. Heart Circ. Physiol. 284, H2083–2090 (2003).

  53. 53

    Nedergaard, M. New roles for astrocytes: redefining the functional architecture of the brain. Trends Neurosci. 26, 523–530 (2003).

  54. 54

    Paulson, O. B. & Newman, E. A. Does the release of potassium from astrocyte endfeet regulate cerebral blood flow? Science 237, 896–898 (1987).

  55. 55

    Harder, D. R., Zhang, C. & Gebremedhin, D. Astrocytes function in matching blood flow to metabolic activity. News Physiol. Sci. 17, 27–31 (2002).

  56. 56

    Rosenblum, W. Cerebral microcirculation: a review emphasizing the interrelationship of local blood flow and neuronal function. Angiology 16, 485–507 (1965).

  57. 57

    Zonta, M. et al. Neuron-to-astrocyte signaling is central to the dynamic control of brain microcirculation. Nature Neurosci. 6, 43–50 (2003). This paper provides evidence that calcium changes in astrocytic end-feet control local vascular resistance.

  58. 58

    Zonta, M. et al. Glutamate-mediated cytosolic calcium oscillations regulate a pulsatile prostaglandin release from cultured rat astrocytes. J. Physiol. (Lond.) 553, 407–414 (2003).

  59. 59

    Duling, B. R. et al. Vasomotor control: functional hyperemia and beyond. Federation Proc. 46, 251–263 (1987).

  60. 60

    Cox, S. B., Woolsey, T. A. & Rovainen, C. M. Localized dynamic changes in cortical blood flow with whisker stimulation corresponds to matched vascular and neuronal architecture of rat barrels. J. Cereb. Blood Flow Metab. 13, 899–913 (1993).

  61. 61

    Erinjeri, J. P. & Woolsey, T. A. Spatial integration of vascular changes with neural activity in mouse cortex. J. Cereb. Blood Flow Metab. 22, 353–360 (2002).

  62. 62

    Ngai, A. C., Ko, K. R., Morii, S. & Winn, H. R. Effect of sciatic nerve stimulation on pial arterioles in rats. Am. J. Physiol. 254, H133–139 (1988).

  63. 63

    Iadecola, C., Yang, G., Ebner, T. & Cheng, G. Local and propagated vascular responses evoked by focal synaptic activity in cerebellar cortex. J. Neurophysiol. 78, 651–659 (1997).

  64. 64

    Ibayashi, S. et al. Lack of sympathetic and cholinergic influences on the cerebral vasodilation caused by sciatic nerve stimulation in the rat. J. Cereb. Blood Flow Metab. 11, 678–683 (1991).

  65. 65

    Dietrich, H. H., Kajita, T. & Dacey, R. G. Local and conducted vasomotor responses in isolated rat cerebral arterioles. Am. J. Physiol. Heart Circ. Physiol. 271, H1109–1116 (1996).

  66. 66

    Fujii, K., Faraci, F. & Heistad, D. D. Flow-mediated vasodilation of the basilar artery in vivo. Circ. Res. 69, 697–705 (1991).

  67. 67

    Busse, R. & Fleming, I. Regulation of endothelium-derived vasoactive autacoid production by hemodynamic forces. Trends Pharmacol. Sci. 24, 24–29 (2003).

  68. 68

    Iadecola, C. in Cerebrovascular Diseases (eds Ginsberg, M. D. & Bogousslavsky, J.) 319–332 (Blackwell Science, Cambridge, Massachusetts, 1998).

  69. 69

    Faraci, F. M. & Heistad, D. D. Regulation of the cerebral circulation: role of endothelium and potassium channels. Physiol. Rev. 78, 53–97 (1998). This review provides a detailed account of the endothelial regulation of the cerebral circulation.

  70. 70

    Mayhan, W. G. Cerebral circulation during diabetes mellitus. Pharmacol. Ther. 57, 377–391 (1993).

  71. 71

    Kazama, K., Wang, G., Frys, K., Anrather, J. & Iadecola, C. Angiotensin II attenuates functional hyperemia in the mouse somatosensory cortex. Am. J. Physiol. Heart Circ. Physiol. 285, H1890–1899 (2003).

  72. 72

    Kudo, T. et al. Are cerebrovascular factors involved in Alzheimer's disease? Neurobiol. Aging 21, 215–224 (2000).

  73. 73

    de la Torre, J. C. Alzheimer disease as a vascular disorder: nosological evidence. Stroke 33, 1152–1162 (2002). References 73, 74 and 89 summarize the evidence that vascular factors might contribute to AD.

  74. 74

    Kalaria, R. N. The role of cerebral ischemia in Alzheimer's disease. Neurobiol. Aging 21, 321–330 (2000).

  75. 75

    Morris, J. C. Dementia update 2003. Alzheimer Dis. Assoc. Disord. 17, 245–258 (2003).

  76. 76

    Lee, V. M., Goedert, M. & Trojanowski, J. Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24, 1121–1159 (2001).

  77. 77

    Selkoe, D. J. & Schenk, D. Alzheimer's Disease: molecular understanding predicts amyloid-based therapeutics. Annu. Rev. Pharmacol. Toxicol. 43, 545–584 (2003).

  78. 78

    Glenner, G. G. & Wong, C. W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885–890 (1984).

  79. 79

    Glenner, G. G. & Wong, C. W. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun. 122, 1131–1135 (1984).

  80. 80

    Roher, A. E. et al. β-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc. Natl Acad. Sci. USA 90, 10836–10840 (1993).

  81. 81

    Price, D. L. & Sisodia, S. S. Mutant genes in familial Alzheimer's disease and transgenic models. Annu. Rev. Neurosci. 21, 479–505 (1998).

  82. 82

    Mattson, M. P. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol. Rev. 77, 1081–1132 (1997). A comprehensive review of the cellular biology of Aβ.

  83. 83

    Christie, R., Yamada, M., Moskowitz, M. & Hyman, B. Structural and functional disruption of vascular smooth muscle cells in a transgenic mouse model of amyloid angiopathy. Am. J. Pathol. 158, 1065–1071 (2001).

  84. 84

    Abramov, A. Y., Canevari, L. & Duchen, M. R. β-amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. J. Neurosci. 24, 565–575 (2004).

  85. 85

    Yin, K. J., Lee, J. M., Chen, S. D., Xu, J. & Hsu, C. Y. Amyloid-β induces Smac release via AP-1/Bim activation in cerebral endothelial cells. J. Neurosci. 22, 9764–9770 (2002).

  86. 86

    Lee, J. T. et al. Amyloid-β peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. J. Cell Biol. 164, 123–131 (2004).

  87. 87

    Hardy, J. & Allsop, D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 12, 383–388 (1991).

  88. 88

    McKhann, G. et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939–944 (1984).

  89. 89

    Farkas, E. & Luiten, P. G. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog. Neurobiol. 64, 575–611 (2001).

  90. 90

    Brun, A. & Englund, E. A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. Ann. Neurol. 19, 253–262 (1986).

  91. 91

    Lee, B. C., Mintun, M., Buckner, R. L. & Morris, J. C. Imaging of Alzheimer's disease. J. Neuroimaging 13, 199–214 (2003).

  92. 92

    Rapoport, S. I. Functional brain imaging to identify affected subjects genetically at risk for Alzheimer's disease. Proc. Natl Acad. Sci. USA 97, 5696–5698 (2000).

  93. 93

    Jagust, W. J. Neuroimaging in dementia. Neurol. Clin. 18, 885–902 (2000).

  94. 94

    Snowdon, D. A. Healthy aging and dementia: findings from the Nun Study. Ann. Intern. Med. 139, 450–454 (2003).

  95. 95

    Roher, A. E. et al. Circle of Willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. Arterioscler. Thromb. Vasc. Biol. 23, 2055–2062 (2003).

  96. 96

    Iadecola, C. Atherosclerosis and neurodegeneration: unexpected conspirators in Alzheimer's dementia. Arterioscler. Thromb. Vasc. Biol. 23, 1951–1953 (2003).

  97. 97

    Thomas, T., Thomas, G., McLendon, C., Sutton, T. & Mullan, M. β-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 380, 168–171 (1996). This paper provided the first evidence that Aβ influences vascular reactivity and that the effect is mediated by free radicals.

  98. 98

    Crawford, F., Suo, Z., Fang, C. & Mullan, M. Characteristics of the in vitro vasoactivity of β-amyloid peptides. Exp. Neurol. 150, 159–168 (1998).

  99. 99

    Paris, D. et al. Vasoactive effects of Aβ in isolated human cerebrovessels and in a transgenic mouse model of Alzheimer's disease: role of inflammation. Neurol. Res. 25, 642–651 (2003).

  100. 100

    Niwa, K. et al. Aβ-peptides enhance vasoconstriction in cerebral circulation. Am. J. Physiol. Heart Circ. Physiol. 281, H2417–2424 (2001).

  101. 101

    Hsiao, K. et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274, 99–102 (1996).

  102. 102

    Westerman, M. A. et al. The relationship between Aβ and memory in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 22, 1858–1867 (2002).

  103. 103

    Kawarabayashi, T. et al. Age-dependent changes in brain, CSF, and plasma amyloid β protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 21, 372–381 (2001).

  104. 104

    Iadecola, C. et al. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nature Neurosci. 2, 157–161 (1999). This paper demonstrates that mice overexpressing App have altered endothelium-dependent CBF responses because of vascular oxidative stress.

  105. 105

    Niwa, K. et al. Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am. J. Physiol. Heart. Circ. Physiol. 283, H315–323 (2002).

  106. 106

    Niwa, K. et al. Aβ1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc. Natl Acad. Sci. USA 97, 9735–9740 (2000). This paper provided the first demonstration that Aβ inhibits functional hyperaemia in mice overexpressing App.

  107. 107

    Niwa, K., Carlson, G. A. & Iadecola, C. Exogenous Aβ1-40 reproduces cerebrovascular alterations resulting from amyloid precursor protein overexpression in mice. J. Cereb. Blood Flow Metab. 20, 1659–1668 (2000).

  108. 108

    Deane, R. et al. RAGE mediates amyloid-beta peptide transport across the blood–brain barrier and accumulation in brain. Nature Med. 9, 907–913 (2003). References 108 and 112 demonstrate that Aβ is transported across the blood–brain barrier in both directions, indicating that CBF can contribute to brain Aβ accumulation and/or clearance.

  109. 109

    Alonzo, N. C., Hyman, B. T., Rebeck, G. W. & Greenberg, S. M. Progression of cerebral amyloid angiopathy: accumulation of amyloid-β40 in affected vessels. J. Neuropathol. Exp. Neurol. 57, 353–359 (1998).

  110. 110

    Kayed, R. et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486–489 (2003).

  111. 111

    Klein, W. L., Krafft, G. A. & Finch, C. E. Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci. 24, 219–224 (2001).

  112. 112

    DeMattos, R. B., Bales, K. R., Cummins, D. J., Paul, S. M. & Holtzman, D. M. Brain to plasma amyloid-β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295, 2264–2267 (2002).

  113. 113

    Zhang, F., Eckman, C., Younkin, S., Hsiao, K. K. & Iadecola, C. Increased susceptibility to ischemic brain damage in transgenic mice overexpressing the amyloid precursor protein. J. Neurosci. 17, 7655–7661 (1997).

  114. 114

    Koistinaho, M. et al. β-amyloid precursor protein transgenic mice that harbor diffuse Aβ deposits but do not form plaques show increased ischemic vulnerability: role of inflammation. Proc. Natl Acad. Sci. USA 99, 1610–1615 (2002).

  115. 115

    De Meyer, G. R. et al. Platelet phagocytosis and processing of β-amyloid precursor protein as a mechanism of macrophage activation in atherosclerosis. Circ. Res. 90, 1197–1204 (2002).

  116. 116

    Moore, K. J. et al. A CD36-initiated signaling cascade mediates inflammatory effects of β-amyloid. J. Biol. Chem. 277, 47373–47379 (2002).

  117. 117

    Wolozin, B. Cholesterol and the biology of Alzheimer's disease. Neuron 41, 7–10 (2004).

  118. 118

    Van Nostrand, W. E., Schmaier, A. H., Farrow, J. S. & Cunningham, D. D. Protease nexin-II (amyloid β-protein precursor): a platelet α-granule protein. Science 248, 745–748 (1990).

  119. 119

    Droge, W. Free radicals in the physiological control of cell function. Physiol. Rev. 82, 47–95 (2002).

  120. 120

    Park, L. et al. Aβ-induced vascular oxidative stress and attenuation of functional hyperemia in mouse somatosensory cortex. J. Cereb. Blood Flow Metab. 24, 334–342 (2004).

  121. 121

    Faraci, F. M. Hyperhomocysteinemia: a million ways to lose control. Arterioscler. Thromb. Vasc. Biol. 23, 371–373 (2003).

  122. 122

    Cai, H., Griendling, K. K. & Harrison, D. G. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol. Sci. 24, 471–478 (2003).

  123. 123

    Iadecola, C. & Gorelick, P. B. Hypertension, angiotensin, and stroke: beyond blood pressure. Stroke 35, 348–350 (2004).

  124. 124

    Della Bianca, V., Dusi, S., Bianchini, E., Dal Pra, I. & Rossi, F. β-amyloid activates the O-2 forming NADPH oxidase in microglia, monocytes, and neutrophils. A possible inflammatory mechanism of neuronal damage in Alzheimer's disease. J. Biol. Chem. 274, 15493–15499 (1999).

  125. 125

    Parvathenani, L. K. et al. P2X7 mediates superoxide production in primary microglia and is up-regulated in a transgenic mouse model of Alzheimer's disease. J. Biol. Chem. 278, 13309–13317 (2003).

  126. 126

    Shimohama, S. et al. Activation of NADPH oxidase in Alzheimer's disease brains. Biochem. Biophys. Res. Commun. 273, 5–9 (2000).

  127. 127

    Hensley, K. et al. A model for β-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc. Natl Acad. Sci. USA 91, 3270–3274 (1994).

  128. 128

    Zou, M. H., Leist, M. & Ullrich, V. Selective nitration of prostacyclin synthase and defective vasorelaxation in atherosclerotic bovine coronary arteries. Am. J. Pathol. 154, 1359–1365 (1999).

  129. 129

    Guo, W. et al. Quantitative assessment of tyrosine nitration of manganese superoxide dismutase in angiotensin II-infused rat kidney. Am. J. Physiol. Heart Circ. Physiol. 285, H1396–1403 (2003).

  130. 130

    Soriano, F. G., Virag, L. & Szabo, C. Diabetic endothelial dysfunction: role of reactive oxygen and nitrogen species production and poly(ADP-ribose) polymerase activation. J. Mol. Med. 79, 437–448 (2001).

  131. 131

    Katusic, Z. S. Vascular endothelial dysfunction: does tetrahydrobiopterin play a role? Am. J. Physiol. Heart Circ. Physiol. 281, H981–986 (2001).

  132. 132

    Walsh, D. M. et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535–539 (2002).

  133. 133

    Ikegaya, Y. et al. β-amyloid enhances glial glutamate uptake activity and attenuates synaptic efficacy. J. Biol. Chem. 277, 32180–32186 (2002).

  134. 134

    Tong, X. K. & Hamel, E. Regional cholinergic denervation of cortical microvessels and nitric oxide synthase-containing neurons in Alzheimer's disease. Neuroscience 92, 163–175 (1999).

  135. 135

    Abe, K., Tanzi, R. E. & Kogure, K. Selective induction of Kunitz-type protease inhibitor domain-containing amyloid precursor protein mRNA after persistent focal ischemia in rat cerebral cortex. Neurosci. Lett. 125, 172–174 (1991).

  136. 136

    Uryu, K. et al. Repetitive mild brain trauma accelerates Aβ deposition, lipid peroxidation, and cognitive impairment in a transgenic mouse model of Alzheimer amyloidosis. J. Neurosci. 22, 446–454 (2002).

  137. 137

    Yokota, M., Saido, T. C., Tani, E., Yamaura, I. & Minami, N. Cytotoxic fragment of amyloid precursor protein accumulates in hippocampus after global forebrain ischemia. J. Cereb. Blood Flow Metab. 16, 1219–1223 (1996).

  138. 138

    Hartlage-Rubsamen, M. et al. Astrocytic expression of the Alzheimer's disease β-secretase (BACE1) is stimulus-dependent. Glia 41, 169–179 (2003).

  139. 139

    Smith, C. D. et al. Altered brain activation in cognitively intact individuals at high risk for Alzheimer's disease. Neurology 53, 1391–1396 (1999).

  140. 140

    Bookheimer, S. Y. et al. Patterns of brain activation in people at risk for Alzheimer's disease. N. Engl. J. Med. 343, 450–456 (2000).

  141. 141

    Mentis, M. J. et al. Increasing required neural response to expose abnormal brain function in mild versus moderate or severe Alzheimer's disease: PET study using parametric visual stimulation. Am. J. Psychiatr. 155, 785–794 (1998).

  142. 142

    Mies, G., Ishimaru, S., Xie, Y., Seo, K. & Hossmann, K. A. Ischemic thresholds of cerebral protein synthesis and energy state following middle cerebral artery occlusion in rat. J. Cereb. Blood Flow Metab. 11, 753–761 (1991).

  143. 143

    Martin, K. C., Barad, M. & Kandel, E. R. Local protein synthesis and its role in synapse-specific plasticity. Curr. Opin. Neurobiol. 10, 587–592 (2000).

  144. 144

    Debiec, J., LeDoux, J. E. & Nader, K. Cellular and systems reconsolidation in the hippocampus. Neuron 36, 527–538 (2002).

  145. 145

    Kleim, J. A. et al. Functional organization of adult motor cortex is dependent upon continued protein synthesis. Neuron 40, 167–176 (2003).

  146. 146

    Moody, D. M., Bell, M. A. & Challa, V. R. Features of the cerebral vascular pattern that predict vulnerability to perfusion or oxygenation deficiency: an anatomic study. Am. J. Neuroradiol. 11, 431–439 (1990).

  147. 147

    Matsushita, K. et al. Periventricular white matter lucency and cerebral blood flow autoregulation in hypertensive patients. Hypertension 23, 565–568 (1994).

  148. 148

    Barber, R. et al. White matter lesions on magnetic resonance imaging in dementia with Lewy bodies, Alzheimer's disease, vascular dementia, and normal aging. J. Neurol. Neurosurg. Psychiatr. 67, 66–72 (1999).

  149. 149

    Gretarsdottir, S. et al. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nature Genet. 35, 131–138 (2003).

  150. 150

    Lo, E. H., Dalkara, T. & Moskowitz, M. A. Mechanisms, challenges and opportunities in stroke. Nature Rev. Neurosci. 4, 399–415 (2003). A critical appraisal of the mechanisms of cerebral ischaemia with emphasis on the neurovascular unit.

  151. 151

    Mosso, A. Ueber den Kreislauf des Blutes im Menschlichen Gehirn (Viet, Leipzig, 1881).

  152. 152

    Mosso, A. La Temperatura del Cervello (Fratelli Treves, Milano, 1894).

  153. 153

    Kety, S. S. & Schmidt, C. F. The nitrous oxide method for the quantitative determination of cerebral blood flow in man: theory, procedure and normal values. J. Clin. Invest. 27, 476–483 (1948).

  154. 154

    Lassen, N. A. & Ingvar, D. H. The blood flow of the cerebral cortex determined by radioactive krypton. Experientia 17, 42–43 (1961).

  155. 155

    Raichle, M. E. in The Nervous System. Volume 5: Higher Functions of the Brain, Part 2 (ed Plum, F.) 643–674 (American Physiological Society, Bethesda, 1987).

  156. 156

    Fox, P. T. & Raichle, M. E. Focal physiological uncoupling of cerebral blood flow and oxidative metabolism during somatosensory stimulation in human subjects. Proc. Natl Acad. Sci. USA 83, 1140–1144 (1986).

  157. 157

    Fox, P. T., Raichle, M. E., Mintun, M. A. & Dence, C. Nonoxidative glucose consumption during focal physiological neural activity. Science 241, 462–464 (1988).

  158. 158

    Ogawa, S., Lee, T. M., Kay, A. R. & Tank, D. W. Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc. Natl Acad. Sci. USA 87, 9868–9872 (1990).

  159. 159

    Ogawa, S. et al. Intrinsic signal changes accompanying sensory stimulation: Functional brain mapping with magnetic resonance imaging. Proc. Natl Acad. Sci. USA 89, 5951–5955 (1992).

  160. 160

    Kwong, K. K. et al. Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. Proc. Natl Acad. Sci. USA 89, 5675–5679 (1992).

  161. 161

    Bandettini, P. A., Wong, E. C., Hinks, R. S., Tikofsky, R. S. & Hyde, J. S. Time course EPI of human brain function during task activation. Magn. Reson. Med. 25, 390–397 (1992).

  162. 162

    Ugurbil, K., Toth, L. & Kim, D. S. How accurate is magnetic resonance imaging of brain function? Trends Neurosci. 26, 108–114 (2003).

  163. 163

    Woolsey, T. A. et al. Neuronal units linked to microvascular modules in cerebral cortex: response elements for imaging the brain. Cereb. Cortex 6, 647–660 (1996).

  164. 164

    Stroke Progress Review Group. Report of the Stroke Progress Review Group (National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, 2002). This report outlines outstanding issues and future directions in research that is related to cerebrovascular diseases and stroke.

  165. 165

    del Zoppo, G. J. & Mabuchi, T. Cerebral microvessel responses to focal ischemia. J. Cereb. Blood Flow Metab. 23, 879–894 (2003). An insightful review of the changes that cerebral ischaemia induces in the neurovascular unit.

  166. 166

    Jones, E. G. On the mode of entry of blood vessels into the cerebral cortex. J. Anat. 106, 507–520 (1970). References 166 and 174 provide a detailed description of the relationship between penetrating cerebral blood vessels and brain cells.

  167. 167

    Peters, A., Palay, S. & Webster, H. D. The Fine Structure of the Nervous System (Oxford University Press, New York, 1991).

  168. 168

    Golding, E. M., Marrelli, S. P., You, J. & Bryan, R. M. Jr. Endothelium-derived hyperpolarizing factor in the brain: a new regulator of cerebral blood flow? Stroke 33, 661–663 (2002).

  169. 169

    Segal, S. S. Integration of blood flow control to skeletal muscle: key role of feed arteries. Acta Physiol. Scand. 168, 511–518 (2000).

  170. 170

    Somlyo, A. P., Wu, X., Walker, L. A. & Somlyo, A. V. Pharmacomechanical coupling: the role of calcium, G-proteins, kinases and phosphatases. Rev. Physiol. Biochem. Pharmacol. 134, 201–234 (1999).

  171. 171

    Prewitt, R. L., Rice, D. C. & Dobrian, A. D. Adaptation of resistance arteries to increases in pressure. Microcirculation 9, 295–304 (2002).

  172. 172

    Lagaud, G., Karicheti, V., Knot, H. J., Christ, G. J. & Laher, I. Inhibitors of gap junctions attenuate myogenic tone in cerebral arteries. Am. J. Physiol. Heart Circ. Physiol. 283, H2177–2186 (2002).

  173. 173

    Kawamura, H. et al. ATP: a vasoactive signal in the pericyte-containing microvasculature of the rat retina. J. Physiol. (Lond.) 551, 787–799 (2003).

  174. 174

    Maynard, E. A., Schultz, R. L. & Pease, D. C. Electron microscopy of the vascular bed of rat cerebral cortex. Am. J. Anat. 100, 409–433 (1957).

  175. 175

    Simard, M., Arcuino, G., Takano, T., Liu, Q. S. & Nedergaard, M. Signaling at the gliovascular interface. J. Neurosci. 23, 9254–9262 (2003).

  176. 176

    Pellerin, L. & Magistretti, P. J. Food for thought: challenging the dogmas. J. Cereb. Blood Flow Metab. 23, 1282–1286 (2003). This paper articulates some of the issues surrounding the controversy on the role of astrocytes in neuronal energy metabolism.

  177. 177

    Newman, E. A. New roles for astrocytes: regulation of synaptic transmission. Trends Neurosci. 26, 536–542 (2003). A lucid appraisal of the evidence that astrocytes are involved in synaptic signalling.

  178. 178

    Edvinsson, L. & Hamel, E. in Cerebral Blood Flow and Metabolism (eds Edvinsson, L. & Krause, D. N.) 43–67 (Lippincott, Williams and Wilkins, Philadelphia, 2002).

  179. 179

    Hachinski, V. C., Lassen, N. A. & Marshall, J. Multi-infarct dementia. A cause of mental deterioration in the elderly. Lancet 2, 207–210 (1974).

  180. 180

    Iadecola, C. & Gorelick, P. B. Converging pathogenic mechanisms in vascular and neurodegenerative dementia. Stroke 34, 335–337 (2003).

  181. 181

    Smith, A. J. et al. Cerebral energetics and spiking frequency: the neurophysiological basis of fMRI. Proc. Natl Acad. Sci. USA 99, 10765–10770 (2002).

  182. 182

    Rees, G., Friston, K. & Koch, C. A direct quantitative relationship between the functional properties of human and macaque V5. Nature Neurosci. 3, 716–723 (2000).

  183. 183

    Murphy, S., Rich, G., Orgren, K. I., Moore, S. A. & Faraci, F. M. Astrocyte-derived lipoxygenase product evokes endothelium-dependent relaxation of the basilar artery. J. Neurosci. Res. 38, 314–318 (1994).

Download references

Acknowledgements

Supported by grants from the National Institutes of Health. The author is the recipient of a Javits award from the National Institute of Neurological Disorders and Stroke. J. Victor and V. Pickel provided helpful comments. The work of many colleagues could not be cited because of space limitations.

Author information

Affiliations

Authors

Ethics declarations

Competing interests

The author declares no competing financial interests.

Related links

Related links

DATABASES

Entrez Gene

App

OMIM

Alzheimer disease

Glossary

CYCLOOXYGENASE

Rate-limiting enzyme for the synthesis of prostanoids from arachidonic acid.

P450 EPOXYGENASE

Family of enzymes that synthesizes epoxyeicosatrienoic acids and hydroxyeicosatrienoic acids from arachidonic acid.

CYCLIN D2

An enzyme that controls the cell cycle by activating cyclin-dependent kinases leading to phosphorylation of cell cycle regulatory proteins.

STELLATE INTERNEURONS

Inhibitory interneurons located in the outer layer of the cerebellar cortex, or molecular layer.

PROSTANOIDS

Cyclooxygenase reaction products including prostaglandins and thromboxanes.

SWEDISH MUTATION

Abnormality in the amyloid precursor protein gene that was discovered in a Swedish family that has an unusually high incidence of early-onset Alzheimer's disease.

SCAVENGER RECEPTOR

Membrane glycoprotein that mediates the recognition and uptake of various negatively charged macromolecules.

NORLEUCINE

An unnatural amino acid that is used experimentally to study protein structure and function.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Iadecola, C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 5, 347–360 (2004). https://doi.org/10.1038/nrn1387

Download citation

Further reading